Lu120819: mitochondrial modulation for diseases driven by cellular stress

Lu120819 is LUTERION's lead investigational therapeutic platform. The candidate is being developed to modulate mitochondrial and immune-metabolic responses under pathological stress.

Lu120819 is a chemically defined liquid formulation of a single isolated active — Luterion™ nanoparticles — with two functional excipients. It is a discrete, purified entity manufactured to a defined specification.

LUTERION's scientific strategy is based on the biological connection between mitochondrial dysfunction, maladaptive immune signaling, and impaired recovery after cellular or tissue injury.

Mitochondrial Dysfunction

Lu120819 is being developed for diseases where mitochondrial dysfunction contributes to pathological stress responses and impaired cellular recovery.

Immune Dysregulation

LUTERION's host-directed strategy focuses on immune-metabolic biology rather than direct pathogen- or symptom-only intervention.

Impaired Tissue Recovery

The platform is being explored in disease areas involving tissue injury, remodeling, and insufficient recovery from cellular stress.

        ◦
        
        Characterization & Quality

A defined, fully characterized nanoparticle

Lu120819 is a monodisperse aqueous nanoparticle suspension manufactured and released to a defined specification. Every batch is characterized for identity, particle size and distribution, particle concentration, chemical purity, and microbiological quality.

Analytical control relies on orthogonal, validated methods — microfluidic resistive pulse sensing for particle metrics, RP-HPLC for active assay, and high-resolution LC-MS/MS (QTOF) for purity — following European Pharmacopoeia procedures where applicable.

Scanning electron micrograph of Lu120819 nanoparticles — Scanning electron micrograph of Luterion™ nanoparticles in Lu120819 — uniform, near-spherical morphology.

Representative release specifications Lu120819-200

Physical formClear to light-yellow aqueous liquid

Particle size (D50)59–72 nm · narrow distribution (Span ≤ 1.5)

Particle concentration5×10⁸ – 5×10⁹ particles/mL

Chemical purityTotal impurities ≤ 1.0% · any individual < 0.10%

Microbial & endotoxinWithin pharmacopeial limits (EP)

Osmolality150–200 mOsmol/kg

Representative specifications from a characterized pilot batch. Methods per European Pharmacopoeia and validated in-house procedures; results on file.

See where Lu120819 is being developed.

View Pipeline→